Halberd Corp (ID) (HALB)

Time to fire up the station wagon...

I okay squidster, I'll explain this one more time.
Just like when that lone Cstore in Florida needed more CBD Gummies from BIEI, Mr. Hartless will get in his car and drive them straight from Pa. to Fl.
🤣 🤣 🤣

No rev, no sales, no cash how are they shipping anything, anywhere?
https://www.otcmarkets.com/file/company/financial-report/574107/content

Definitely need a better pump system:

https://x.com/prism_mediawire/status/2067583961253961787/photo/1

https://x.com/prism_mediawire/status/2067583961253961787/photo/2

https://prismmediawire.com/halberd-corporation-ships-latest-neurosense-ai-version-advancing-voice-based-behavioral-monitoring/

In Athena Telemedicine Partners LLC (ATP), four partners combined: Halberd Corp, AthenaGTX, Exalted Warriors and a fourth unknown partner. Testing is under CRADA (A Cooperative Research and Development Agreement (CRADA) is any formal written agreement between one or more Federal agencies (here: army) and one or more non-Federal parties).

Not sure whether the second round of animal testing at MSU, the nasal spray to treat/prevent TBI, has started. Hartman leads, together with Russell Carr

WatchDawg second round of testing started 2 months ago, Mark Darrah (AthenaGTX) is leading

$HALB, latest SP: 0.00098

Halberd Corporation Ships Latest NeuroSense AI Version, Advancing Voice-Based Behavioral Monitoring

New milestone delivers repeatable stress and behavioral metrics, AI-assisted summaries, and longitudinal per-subject tracking — on the same pipeline headed for wearable check-ins

MELBOURNE, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) detailed the latest NeuroSense AI metrics – its integrated, voice-based behavioral intelligence platform. This milestone enables brief voice samples to generate consistent, long-term health metrics for research and clinical teams. This latest development milestone successfully turns brief voice samples into repeatable, long-term health metrics for research and clinical care teams. Behavioral health and neurological monitoring often stop at the clinic door. NeuroSense closes that gap with brief voice check-ins that produce repeatable metrics over time — capturing what happens between appointments, not just during them.

What Shipped in This Build

The latest version of the platform introduces a streamlined, four-step pipeline:

Capture: Grabs short, multi-second speech samples and organizes them automatically by patient.
Analyze: Instantly scores real-time stress levels, behavioral changes, and emotional engagement.
Interpret: Generates automated, AI-assisted summaries to give care teams quick, actionable insights.
Track: Logs a secure, seven-day baseline history to help providers catch real-world triggers and time-of-day patterns.
Why it’s a big deal: The core software architecture is already fully optimized. The exact same analysis engine powering today’s desktop demo is designed to power tomorrow’s wearable integration under the company’s "Watchdawg" product roadmap. This creates a single, seamless path from prototype to watch-based check-ins, completely skipping the need for a costly code rebuild when moving to mobile hardware.

Seeking

Halberd Corporation is actively seeking research partners and investors focused on objective, longitudinal behavioral biomarkers across anxiety, PTSD, Traumatic Brain Injury (TBI), and related neurological research.

NeuroSense AI is designed to complement clinical judgment and validated assessment scales — it is not intended to replace formal diagnosis or treatment decisions. Instead, it is designed to test the relationships between uniquely accessible alterations in behavioral factors and the manifestation of biomarkers associated with traumatic brain injury (and, in the future, other medical anomalies). This next round of testing focuses on 5 specific behavioral alterations as it pertains to: first, the commencement of and secondly, the alleviation of, such behavioral factors.

https://prismmediawire.com/halberd-corporation-ships-latest-neurosense-ai-version-advancing-voice-based-behavioral-monitoring/

All provisional and non provisional patents have expired
I could buy the exclusive rights to Felders patents for $250k.
Let's set up conference call, I'll DM you everyone's cell # or you can DM me yours and I'll set it up. LMAO

...and yet https:

Hard to believe it has been 5 yrs. since this was over .04.
Wonder who is still holding .01 or better shares? I have a guess.

👍

About Halberds IP:

Halberd holds the exclusive rights to 5 granted U.S. Patents:
US9,216,386 (expiration date: 2030-03-16)
US8,758,287 (expiration date: 2030-01-12)
US11,186,629 (expiration date: 2038-03-23)
US8,865,733 (expiration date: 2030-06-05)
US12,521,475 (joint ASU, expiration date: 2043-03-17)

Halberd has 8 non-provisional patent applications pending (some joint with ASU and/or Dr. Qiang Chen): US17/883,821 / US17/883,801 / US17/825,132 / US17/747,322 / US17/726,109 / US17/917,592 / US17/528,891 / US17/920,680

Halberd also has 7 provisional patent applications pending and 3 PCT International patent applications: US63/116,561 / US63/231,986 / US63/231,929 / US63/049,441 / US63/193,880 / US63/190.398 / US63/178,354 / PCT/US21/28368 / PCT/US63/173,763 / PCT/US21/26386

(some recent non-provisional patent applications (TBI nasal spray, LDX etcetera) have not yet been published)

Artificial intelligence will revolutionise healthcare research and future treatments.

If theyre pumping theyre doing a poor job at it.

Wonder why the world hasn't caught on to this gem?

Nothing to do with the current iteration of HALB (magic nose spray). This is the same shiat Felder has been working on for over a decade (extracoporeal therapy).
Patent is assigned to ASU, Marv Enterprises/Felder...

No you mix things up...
ASU was not paid in full and the 7 stage research was halted due to HALB lack of funds.
All provisional patent applications have expired and what they are left with is what Dr. Felder/Marv Enterprises brought to the table.
So when I stated Harman has been doing the same thing for 20 yrs (selling shares at your expense) that is completely accurate...LMFAO!!

Take note of the changes in OTC's Security Details page. There is more info. added to every tickers page.
This will help folks to understand the reason for the new pump effort here at HALB.

05/12/2026 - 747,303,413 - 40,000,000 - +5.66

I guess the trading has been so low, that a new pump was bound to happen. Can't sell shares when nobody is trading your stock. 😜

https://www.otcmarkets.com/stock/HALB/security

Let's see if some money can be made?

You mix up things. It was Premier Biomedical who owned the University of Texas (UTEP) in El Paso a large amound. Halberd Corp did research at the Arizona State University, resulting in 1 full US patent, 7 joint non-provisional patent applications and 10 international PCT / provisional patent applications. The research costs ($1,371,782) was paid in full.

Also recently another full non-provisional patent application showed up, related to the TBI nasal spray, being tested at MSU:

Composition for Acutely Decreasing Pathophysiologic Effects from a Concussion and a Method of Administering Thereof
Publication number: 20260109784
Abstract: Composition for acutely decreasing pathophysiologic effects from a concussion includes a quantity of glutamate monoclonal antibody, a quantity of at least one neurosteroid, a quantity of nasal insulin, a quantity of plant-based oil, and a quantity of saline solution, which are homogenously mixed into a spray composition. This composition may further include a quantity of aspartate monoclonal monoclonal antibody and/or a quantity of monomer. The method of administering the nasal-spray composition is preferably done via a sprayer into each nostril of a concussed patient.
Type: Application
Filed: September 27, 2023
Publication date: April 23, 2026
Inventor: Mitchell Steven Felder

This patent application was filed in september '23 and has since been supplemented with additional technology: AI from NeuroSenseAI (89% subsidiary)

Recently Halberd / Felder (MARV) received a fifth full US patent:

Method, device, and product for treating a body fluid of a patient with an inflammatory cytokine storm by binding an antibody to a cytokine antigen in the body fluid to form an antigen-antibody complex that is removed from the body fluid to reduce the amount of the cytokines in the body fluid
Patent number: 12521475

Abstract: An embodiment provides a method for treating a body fluid of a patient with an inflammatory cytokine storm, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an antigen in the body fluid to form an antibody-antigen complex; removing the antibody-antigen complex from the body fluid; and returning the body fluid to the patient. Other aspects are described and claimed.
Type: Grant
Filed: April 8, 2021
Date of Patent: January 13, 2026
Assignees: Arizona Board of Regents on Behalf of Arizona State University, Marv Enterprises LLC
Inventors: Qiang Chen, Collin Bradley Jugler, Haiyan Sun, Adrian Esqueda, Mitchell S. Felder

Halberd's share price: $ 0.001 and market cap of $747K only

Athena Telemedicine Partners LLC: Preparations and the second round of testing the WatchDawg program to treat PTSD started a few months ago. Halberd's (patent pending) LDX compound is part of the program.

Looking for a New Approach to Mental Health Care? 🧠📈
Traditional approaches don't work for everyone. That’s why Athena Telemedicine Partners created the WatchDawg® program—a multi-faceted approach that combines cutting-edge technology with personalized care to help manage PTSD, anxiety, and depression.
Our Phase 2 pilot study is officially underway, and we are expanding our group! We have a limited number of openings for new participants to join the study at no cost.
Why join? This study offers you the opportunity to utilize advanced biometric tracking tools alongside specialized counseling and wellness resources, giving you real-time insights into your health while helping shape the future of virtual mental health care.
Spaces are limited as we finalize our participant list. Take a step toward proactive wellness and see if you qualify today!

Athena Telemedicine Partners LLC is a joint operation: Halberd Corp, AthenaGTX and Exalted Warriors of Tampa

Athena Telemedicine Partners Advances WatchDawg® Program, Preparing for Two New Clinical Trials in 2025

Johnston, Iowa — October 29, 2025 — Athena Telemedicine Partners (ATP), in cooperation with Athena GTX, Inc., announced today that preparations are underway for two additional clinical trials of its innovative WatchDawg® program, set to launch before the end of 2025.

The WatchDawg program integrates wearable patient monitoring technology, telemedicine support, yoga and mindfulness-based therapy, targeted wellness supplements, and clinical counseling to provide a comprehensive, data-driven approach to mental and physical health management. Designed initially to serve individuals struggling with mental health conditions, including PTSD, anxiety, depression, and addiction, the program aims to improve early intervention, stress regulation, and long-term wellness outcomes through a connected, holistic ecosystem of care.

As part of the next phase of development, Athena Telemedicine Partners is also testing a proprietary AI model for mental health risk prediction, developed to enhance the program’s monitoring and intervention capabilities. The model interprets participant data and translates it into an intuitive “stoplight” system—where green indicates stability and well-being, yellow signals moderate concern, and red highlights the need for clinical attention. This visual system empowers users and care teams to quickly identify and respond to changes in mental health status, supporting timely, personalized interventions.

“Our goal with WatchDawg is to make continuous wellness support accessible and effective for those who serve and protect,” said Dr. Mark I. Darrah, CEO of Athena GTX and a founding partner of Athena Telemedicine Partners. “By combining advanced wireless monitoring with telemedicine, yoga, clinical counseling, and now AI-driven mental health insights, we’re building a system that connects mind and body health in a way that’s both measurable and meaningful.”

The upcoming trials will evaluate the effectiveness of WatchDawg’s integrated monitoring and wellness platform in real-world conditions, focusing on outcomes related to stress, recovery, and behavioral health improvement. The trials build upon the initial pilot phase, which demonstrated promising feedback on user experience, monitoring reliability, and participant engagement.

The WatchDawg platform leverages Athena GTX’s proven wireless vital signs monitoring (WVSM®) technology, supported by telehealth tools and personalized wellness interventions. The initiative reflects Athena Telemedicine Partners’ commitment to developing technology-enabled solutions that bridge the gap between remote physiological monitoring, mental wellness, and proactive care.

“These next clinical trials will be key in validating our system including a novel based AI predictive algorithm and preparing WatchDawg for broader implementation,” said a spokesperson for Athena Telemedicine Partners. “Our vision is to empower individuals to take control of their wellness journey through connected care, mindfulness, clinical support, and AI-assisted insight.”

As the company moves toward these 2025 clinical trials, Athena Telemedicine Partners continues to collaborate with research partners, healthcare providers, and wellness professionals to ensure the WatchDawg platform delivers both scientific rigor and human-centered impact.

About Athena Telemedicine Partners (ATP)

Athena Telemedicine Partners, LLC, is based in Johnston, Iowa, and is dedicated to advancing connected care solutions that integrate real-time monitoring, telemedicine, and holistic wellness. The company’s flagship program, WatchDawg, combines wearable technology, yoga therapy, wellness supplements, and clinical counseling to improve health outcomes for veterans, first responders, and individuals in high-demand environments.

NeuroSenseAI corp. is a 89% subsidiary of Halberd Corp:

Jackson Center, PA – May 28, 2026 – Halberd Corporation (OTC: HALB) announced today that NeuroSense AI, the behavioral intelligence platform in development by the Company, has achieved a new engineering milestone: end-to-end processing of externally supplied, long-form voice recordings—including direct-from-file ingestion, feature extraction, and automated visualization suitable for partner review and internal validation workflows.

As research programs scale—particularly those pairing voice with physiology, cardiopulmonary, and neurophysiology measures—the ability to analyze audio as delivered in the field (without re-recording through a microphone) is a prerequisite for reproducible analytics and for the validation and verification (V&V) documentation increasingly expected by sponsors and funding stakeholders. NeuroSense’s updated pipeline is designed to meet that bar by treating data provenance—format, sample rate, channel layout, and processing steps—as first-class inputs to analysis and reporting.

The milestone supports Halberd’s broader strategy of deploying multimodal behavioral intelligence across preclinical and translational research contexts. NeuroSense AI continues to integrate AI-assisted pattern recognition, including advanced interpretation workflows, with objective, time-resolved behavioral signals. Today’s progress extends that approach to human conversational audio used in structured assessment and longitudinal study settings, complementing the platform’s existing emphasis on objective behavioral sensing and interpretation in complex research environments.

Halberd and its collaborators remain focused on transparent methods: distinguishing research and analytics capabilities from any future diagnostic or therapeutic claims, and aligning software documentation with sponsor expectations as programs mature. The Company expects to provide additional technical updates as NeuroSense AI is exercised on larger, multimodal corpora and as integration pathways with complementary modalities—including EEG and biomarker streams—continue to harden.

Yesterday's closing .00079, market cap only $590K. lol

Maybe a hold-out that realizes than 8-9 is better than 1-2?
I think Hatrless is too old to move to another ticker, but wonder if Little Hartless ends up as secretary of another one.
(As part of a deal to relinquish claim to to this one?)
But maybe she wants nothing to do with another one, that doesn't involve Poppy?

Who would be selling at these levels 😅.
Slick Willy only has 52 milly left to sell until fully diluted.

Hartman's been using the same playbook to 20 yrs....

Really?

Trips it is, R/S coming...

I could see it if, you thought it was going even lower.
Seriously, if you thought that, what would be the point in holding for half of .001, or .0008.
If nothing else, you could put it in dozens of other stocks and maybe offset your losses.
Just saying...

Trips again, who would sell at these levels?

That's some funny shiat right there... ASU has nothing to do with HALB, did you forget they owe them $$ and that's why the "research agreement" ended... Didn't the provisional patents and international patent applications expire?
With all of this IP and promise, why is slick willy still selling shares? At your expense.....

About Halberds IP:

Halberd holds the exclusive rights to 5 granted U.S. Patents: US9,216,386 / US8,758,287 / US11,186,629 / US8,865,733 / US12,521,475 (joint ASU)

Halberd has 8 non-provisional patent applications pending (some joint with ASU and/or Dr. Qiang Chen): US17/883,821 / US17/883,801 / US17/825,132 / US17/747,322 / US17/726,109 / US17/917,592 / US17/528,891 / US17/920,680

Halberd also has 7 provisional patent applications pending and 3 PCT International patent applications: US63/116,561 / US63/231,986 / US63/231,929 / US63/049,441 / US63/193,880 / US63/190.398 / US63/178,354 / PCT/US21/28368 / PCT/US63/173,763 / PCT/US21/26386

(some recent non-provisional patent applications (TBI nasal spray, LDX etcetera) have not yet been published)

Artificial intelligence will revolutionise healthcare research and future treatments.

For anyone who played Hartless's last ticker, it was no surprise.
And then the history of this ticker added in.....
Typical Pink behavior IMHO.

So much promise & turned to crap quickly.

Well, luckily, I can do more than 1 at a time, because a person would go hungry trying to make a living off the volume that this one has.

PS: Speaking of......I think what you said is true, but only because nobody else is even playing this one. lol

Trips it is..... Nobody flips this POS better than you.

1/2M sold at trip 9, with only 65K left on the Bid. Good news is, as it sinks, it leaves room for a higher percentage flip. 😜
It got to the point, while in the teens, that a 2-3 point flip was not worth the time it took to happen.
Now the danger is, if there will be enough volume to make a 30-50% flip?????????????????????

They've made no such announcement and nothing on their website states this...

457 million shares is a lot of selling

Yes, there's been dilution, from 290M in April 2020 to 747M in April 2026

Expecting news about funding (gov. grant) and updates about the second animal testing at MSU

HALB now has 5 granted US patents, with some 10 non-provisional patents pending. Also another 9 provisional patent applications pending.